We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ANTIBODIES AGAINST ROR1 AND USES THEREOF
TARGETED CYTOKINE FOR TREATMENT OF MUSCULOSKELETAL DISEASES
Device for X-ray examinations
RAPID DETECTION OF METABOLIC ACTIVITY
DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK
LIQUID PHARMACEUTICAL COMPOSITION COMPRISING NITISINONE
SYSTEM AND METHOD FOR SECURING TISSUE TO BONE
ENHANCED FERMENTATION OF CELLODEXTRINS AND BETA-D-GLUCOSE
METHODS AND USES FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS
SALTS OF SAXAGLIPTIN WITH ORGANIC ACIDS
PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES
CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA